EWEdwards Lifesciences
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. 10-K, Item 1
- Employees
- 16,000
- Headquarters
- Irvine, CA
- CEO
- Bernard J. Zovighian
- Next results
- around Feb 9, 2027
Key numbers
Latest fiscal year, with ten years behind eachWhat changed
10-K filed Feb 25, 2026 against Feb 28, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 11 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Accounting checks | 11 other checks clear | 10-K · XBRL |
| Insiders | No open-market buys in the last 90 days | Form 4 |
| Filings | 2 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 25, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-28. Quoted as filed.
Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results. We use AI and other emerging technologies in various facets of our operations and our business. The legal and regulatory landscape surrounding AI technologies is rapidly evolving…
10-K, Item 1A
Accounting checks
latest 10-K11 of 11 clear 0 worth a look. Checks, not verdicts.
- ✓Receivables +8.3% vs revenue +11.5% (-3.3 pts)
- ✓Cash from operations $1.6B vs net income $1.1B (FY ending 2025-12-31)
- ✓Inventory +3.6% vs revenue +11.5% (-7.9 pts)
- ✓Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓No longer listed: Acquisition of Endotronix, Inc. - Valuation of the Developed Technology; Acquisition of Innovalve Bio Medical Ltd. - Valuation of the IPR&D. Same as last year: Uncertain Tax Positions Related to Intercompany Transfer Pricing
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 4, 20268-K Quarterly results 8-K item 2.02
- Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
About Edwards Lifesciences
10-K, Feb 25, 2026Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades. Since our founder, Miles “Lowell” Edwards, first dreamed of using engineering to address diseases of the human heart, we have steadily built a company on the premise of imagining, building, and realizing a better future for patients.
- Headquarters
- Irvine, CA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had approximately 16,000 employees worldwide, the majority of whom were located in the United States, Singapore, and Costa Rica" (10-K). Address and exchange: SEC's company file.
Permanent link, kept if the ticker changes: /c/sec:0001099800 (SEC's CIK).
Work on EW in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/EW/export.csv") into a cell.